Side-Effects Management

Awareness of the adverse effects of immune checkpoint inhibitors and how to manage them was the focus of several presentations at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference.
The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer.
Real-world experience at the University of Texas M.D. Anderson Cancer Center, Houston, showed that the most frequent immune-related adverse events leading to emergency department visits for patients treated with immune checkpoint inhibitors were diarrhea, colitis, pneumonitis, and dermatitis.
Page 2 of 2
Results 11 - 13 of 13